This segment focuses on the research, development, and commercialization of therapies for cardiorenal diseases, with a primary focus on heart failure and chronic kidney disease. The lead product, FUROSCIX, is a subcutaneous formulation of furosemide delivered via the SmartDose drug delivery system, designed to reduce hospitalizations and improve patient outcomes. Research and development activities include clinical trials to expand the indications for FUROSCIX and explore combination therapies. The company utilizes advanced pharmaceutical formulation techniques and drug delivery technologies. The patient impact is significant, as FUROSCIX offers a convenient alternative to intravenous furosemide, improving quality of life and reducing healthcare costs. Market positioning is centered on addressing unmet needs in heart failure management. Future opportunities include expanding the product portfolio and exploring partnerships to enhance market access and distribution. Regulatory and clinical aspects involve ongoing interactions with the FDA and other regulatory bodies to secure approvals and ensure compliance. Collaborations with West Pharmaceutical Services, Inc. for the SmartDose system are crucial for product delivery.